secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001104659-22-126640
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics enters separation agreement with retiring executive Frank Ruffo
--------------------------------------------------------------------------------

- Frank Ruffo's retirement separation agreement approved; includes consulting deal through March 2, 2023 for $25,000.
- Ruffo will continue vesting of outstanding options and RSUs during the consulting period.
- Exercise period for vested options extended to December 31, 2023.
- Ruffo retains eligibility for 2022 annual bonus and accrued pay/vacation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465922126640/0001104659-22-126640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465922126640/tm2232516d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-126640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer